48-Week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-Infected patients: A systematic review and network meta-analysis
Authors: D A Patel, S J Snedecor, W Yu Tang, L Sudharshan, J W Lim, R Cuffe, S Pulgar, K A Gilchrist, R Refoios Camejo, J Stephens, G Nichols